Inoda, Satoru
Takahashi, Hidenori http://orcid.org/0000-0001-5331-4730
Arai, Yusuke
Tampo, Hironobu
Matsui, Yoshitsugu
Kawashima, Hidetoshi
Yanagi, Yasuo
Article History
Received: 8 September 2022
Revised: 26 February 2023
Accepted: 30 March 2023
First Online: 11 May 2023
Declarations
:
: This retrospective study was approved by the institutional review board of Jichi Medical University (Jichi-CU19-094) and adhered to the tenets of the Declaration of Helsinki. The study procedures followed institutional guidelines.
: Informed consent was obtained in the form of opt-out on the website of the Department of Ophthalmology of Jichi Medical University.
: SI, H Tampo, and YA have no relevant financial or non-financial interests to disclose.H Takahashi is a consultant to Kowa Pharmaceutical, Novartis Pharmaceutical, Bayer Pharmaceutical, Senju Pharmaceutical, Pfizer Pharmaceutica, and Santen Pharmaceutical, and receives salary from DeepEyeVision Inc.YM is a consultant to Alcon Japan, AMO Japan, Novartis Pharmaceuticals, Santen Pharmaceutical, Bayer Pharmaceutical and Senju Pharmaceutical.HK is a consultant to Kowa Pharmaceutical, Novartis Pharmaceuticals, Santen Pharmaceutical, Mitsubishi-Tanabe Pharmaceutical, Senju Pharmaceutical, and the Tochigi Prefectural Ophthalmologists Association.YY is a consultant to Novartis Pharmaceuticals, Bayer Yakuhin, Santen Pharmaceuticals and Senju Pharmaceutical.
: None.